Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors.
about
Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects.Neuronal traffic signals in tardive dyskinesia: not enough "stop" in the motor striatum.Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes.Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
P2860
Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors.
@en
Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors.
@nl
type
label
Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors.
@en
Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors.
@nl
prefLabel
Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors.
@en
Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors.
@nl
P2860
P1433
P1476
Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors.
@en
P2093
Stephen M Stahl
P2860
P304
P356
10.1017/S1092852917000426
P577
2017-08-01T00:00:00Z